EXEL - Exelixis, Inc.
NEXT EARNINGS:
May 12, 2026
EPS Est: $0.76
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$44.40
DETAILS
HIGH:
$54.00
LOW:
$30.00
MEDIAN:
$45.50
CONSENSUS:
$44.40
DOWNSIDE:
1.64%
Market Cap:
12.10B
Volume:
2,648,124
Avg Volume:
2,612,783
52 Week Range:
32.38-49.62
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.42
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,147
IPO Date:
2000-04-17
EPS (TTM):
2.88
P/E Ratio:
15.12
Revenue (TTM):
2.32B
Total Assets:
2.84B
Total Debt:
173.04M
Cash & Equiv:
482.49M
Rev Growth (5Y):
18.6%
EPS Growth (5Y):
51.5%
FCF Growth (5Y):
36.4%
ROCE:
36.6%
Debt/Equity:
0.08
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-10 | $0.94 | $0.77 | +22.1% | $598.7M | $606.7M | -1.3% |
| 2025-11-04 | $0.78 | $0.69 | +13.9% | $597.8M | $590.2M | +1.3% |
| 2025-07-28 | $0.75 | $0.65 | +15.4% | $568.3M | $594.9M | -4.5% |
| 2025-05-13 | $0.62 | $0.36 | +73.1% | $555.4M | $499.6M | +11.2% |
| 2025-02-11 | $0.55 | $0.51 | +7.8% | $566.8M | $563.2M | +0.6% |
| 2024-10-29 | $0.40 | $0.35 | +14.3% | $539.5M | $556.6M | -3.1% |
| 2024-08-06 | $0.77 | $0.30 | +156.7% | $637.2M | $465.0M | +37.0% |
| 2024-04-30 | $0.17 | $0.28 | -39.3% | $425.2M | $460.6M | -7.7% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.32B | 2.17B | 1.83B | 1.61B | 1.43B | 987.54M | 967.77M | 853.83M | 452.48M | 191.45M | 37.17M | 25.11M |
| Net Income | 782.57M | 521.27M | 207.76M | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M | 154.23M | (70.22M) | (169.74M) | (268.54M) |
| EPS | 2.88 | 1.80 | 0.65 | 0.57 | 0.73 | 0.36 | 1.06 | 2.32 | 0.52 | -0.28 | -0.81 | -1.38 |
| Total Assets | 2.84B | 2.95B | 2.94B | 3.07B | 2.62B | 2.14B | 1.89B | 1.42B | 655.29M | 597.54M | 332.34M | 327.96M |
| Total Debt | 173.04M | 190.82M | 189.94M | 190.17M | 51.27M | 49.09M | 50.74M | 14.92M | 14.53M | 189.12M | 381.44M | 361.66M |
| Cash & Equivalents | 482.49M | 217.37M | 262.99M | 501.19M | 647.17M | 319.22M | 266.50M | 314.77M | 183.16M | 151.69M | 141.63M | 80.39M |
| Operating Cash Flow | 884.27M | 699.97M | 333.32M | 362.61M | 400.80M | 208.98M | 526.96M | 415.72M | 165.61M | 206.30M | (141.59M) | (235.41M) |
| Free Cash Flow | 844.34M | 633.79M | 170.35M | 224.16M | 336.58M | 178.64M | 514.12M | 382.42M | 144.47M | 204.59M | (142.03M) | (235.88M) |
| FCF per Share | 3.11 | 2.19 | 0.54 | 0.70 | 1.07 | 0.58 | 1.70 | 1.28 | 0.49 | 0.82 | -0.68 | -1.21 |
| Book Value | 2.16B | 2.24B | 2.26B | 2.49B | 2.21B | 1.88B | 1.69B | 1.29B | 284.96M | 89.32M | (104.30M) | (114.83M) |
| Cash & ST Investments | 1.06B | 1.11B | 995.30M | 1.31B | 1.47B | 1.21B | 852.24M | 693.33M | 387.77M | 419.80M | 167.06M | 144.28M |
| ROC Equity | 0.36 | 0.23 | 0.09 | 0.07 | 0.10 | 0.06 | 0.19 | 0.54 | 0.54 | -0.79 | N/A | N/A |